This company/stock does not appear to be very well known or followed; yet, there are some major players accumulating shares. If you followed today's trading, you saw the price jump up on periodic, significant block buys (see daily chart which shows this).
In other words, the retail buyers do not seem to be influencing the stock's price as much as some major players -- who are not worried about a few pennies here or there -- they want to accumulate large blocks of this stock and are willing to pay significantly in excess of the bid to do it.
This, combined with the large insider/inst'l holdings of this stock, suggests that it is one to hold on to, rather than try to trade up to FDA approval date. Trying to trade on dips is risky as you can miss out on a major move to the upside.
Facts indicate FDA approval is highly likely. This drug is preferable over existing treatment because Aloxi has to be administered through an IV. This drug is administered through a one time injection.
And, this was up nicely on a down day in the market. Looking good!
You can check out AOL Finance for those Insider SEC forms and transactions:
I hear you. I got in at $1.50 and wish I had bought more at that price (which seemed very rich at the time). Who knows - I think this will go higher. It certainly holds its own in a down market and has the upcoming FDA approval date of March 18th as a catalyst. The historical price was very high which is encouraging. Probably the thing I like the most is the high insider and institutional holdings. I am very confident that this is going higher than $2. How much higher - who knows? But that would be a nice return from here for sure.
Good post, altairas2. And I agree with your trading on dips being risky part. You get days like today with nothing much happens, but you also get days like last Wednesday, Friday and this Monday that just take off with double digit gains.
Correct, the Biochronomer links, or bonds. Upon coming into contact internal body fluids, the water in thee fluids reacts with these bonds. Known as hydrolysis. During the hydrolysis of the Biochronomer links, acidic elements are produced in a local micro-environment, in a controlled manner, without impacting the overall neutrality of the drug delivery technology. These elements assist in the continued, controlled erosion of the polymer with a simultaneous, controlled release of the active drug contained within the Biochronomer. By varying the amount of the acidic elements in the Biochronomer, different rates of hydrolysis may be effectively realized. In this manner, delivery times ranging from days to several months can be achieved without continuous intraveneous injections. Its actually very ingenious.